Encompass Health Beats Estimates and Raises FY2026 Outlook, Yet Stock Slides Amid Valuation Concerns

Encompass Health reported net operating revenue of $1.586 billion for the quarter ended March 31, 2026, up 9.0% year‑over‑year and in line with the 9.01% growth cited by market‑trackers. Adjusted EBITDA rose 11.2% to $348.8 million, while income from continuing operations per diluted share jumped 19.6% to $1.77. After accounting for non‑recurring items, adjusted EPS reached $1.93, a 30.4% increase that topped the consensus estimate of $1.51. The company generated $248.2 million of cash from operating activities, translating into $193.8 million of adjusted free cash flow after capital expenditures, underscoring a solid cash conversion profile despite a modest rise in debt‑related expenses.

The results prompted Encompass Health to lift its full‑year 2026 guidance. Net operating revenue is now projected between $6.375 billion and $6.470 billion, up from the prior $6.365‑$6.465 billion range. Adjusted EBITDA guidance was nudged to $1.350‑$1.380 billion, and adjusted earnings per share are expected to fall between $5.89 and $6.11, compared with the earlier $5.81‑$6.10 window. The incremental guidance reflects the company’s confidence that the 9% top‑line momentum will sustain through the year, and that operating efficiencies will continue to improve as the network scales.

Operationally, the firm is expanding its capacity at a rapid clip. In Q1 it opened a new 49‑bed inpatient rehabilitation hospital in Irmo, South Carolina, and added 44 beds across existing facilities. Management outlined a 2026 rollout plan that includes eight new hospitals adding a total of 389 beds and an additional 175 beds in current locations. Same‑store discharge growth remained positive, and net patient revenue per discharge rose modestly to $22,633, indicating that the added capacity is being filled at rates comparable to existing sites.

From a market perspective, EHC’s stock sits at roughly $100, down 5.6% year‑to‑date and trading 21.9% below its 52‑week high of $127.99. Technical indicators suggest the shares are oversold: the 14‑day RSI is 23.7, and the price is below both the 50‑day and 200‑day moving averages (96.9% and 89.7% of those averages, respectively). Relative volume is more than double the average, pointing to heightened trading activity around the earnings release. Analyst consensus price targets hover around $153, implying a potential upside of about 53% if the stock reverts to those expectations.

Investors must balance the upside from robust top‑line growth and a generous guidance upgrade against several risk factors. The company’s reliance on Medicare and Medicaid reimbursements makes it vulnerable to policy shifts and rate cuts. Ongoing capital deployment—nearly $150 million in quarterly capex—will increase debt levels, with interest expense and debt‑related amortization estimated at roughly $135 million for the year. Moreover, the broader health‑care sector has been lagging the S&P 500, with EHC underperforming the index by roughly 11% on a YTD basis. Nevertheless, the combination of strong cash flow, expanding bed inventory, and a sizable valuation gap may present a compelling entry point for long‑term investors who can tolerate short‑term volatility.

Overall, Encompass Health’s Q1 performance validates its growth narrative and justifies a more optimistic FY2026 outlook. While the immediate market reaction was muted, the company’s expanding footprint, disciplined earnings growth, and attractive free‑cash‑flow generation could translate into meaningful shareholder value, especially if the stock can recover from its current oversold condition.